TOPICS

Category: Rosacea

Biophotonic Therapy with Fluorescent Light Energy Decreases Facial Erythema, Improves Signs and Symptoms of Rosacea, and Increases Patient Satisfaction: A Postmarket Study

J Clin Aesthet Dermatol. 2021;14(7):16–21 by Martin Wade, BMed Sci, MBBS, FACD; Vanessa Charest, BSc; Bruno Ballardin, B. Eng, MBA; Deirdre Edge, PhD; and Michael Canova Engelbrecht Nielsen, PhD Dr. Wade, Ms. Charest, and Mr. Ballardin are with the London Skin and Hair Clinic in London, England. Drs. Edge and Nielsen are with Guangdong Klox

CONTINUE READING »

Selected Abstracts from MauiDerm 2021 for Dermatologists

J Clin Aesthet Dermatol. 2021;14(5 Suppl 1):S8–S30. © µ µ ? A message from the Guest Editor and MauiDerm Program Director, George Martin, MD Dear Colleagues:  The 2021 edition of the Maui Derm for Dermatologists meeting had a variety of clinical and scientific data presented, but not just at the podium. A wide range of clinically

CONTINUE READING »

Topical Oxymetazoline Hydrochloride Cream 1% for the Treatment of Persistent Facial Erythema of Rosacea in Adults: A Comprehensive Review of Current Evidence

J Clin Aesthet Dermatol. 2021;14(3):32–37. by James Q. Del Rosso, DO, and Emil Tanghetti, MD Dr. Del Rosso is Research Director at JDR Dermatology Research in Las Vegas, Nevada, is with Thomas Dermatology in Las Vegas, Nevada, and is an adjunct clinical professor of dermatology at Touro University Nevada in Henderson, Nevada. Dr. Tanghetti is

CONTINUE READING »

Botulinum Toxin: An Effective Treatment for Flushing and Persistent Erythema in Rosacea

J Clin Aesthet Dermatol. 2021;14(3):42–45. by Andres Luque, MD; AIDA PAOLA ROJAS, MD; Andrea Ortiz-Florez, MD; and Juliana Perez-Bernal, MD All authors are with Hospital Universitario Centro Dermatológico Federico Lleras in Bogotá, Colombia. FUNDING: No funding was provided for this article. DISCLOSURES: The authors report no conflicts of interest relevant to the content of this

CONTINUE READING »

Safety and Pharmacokinetics of FMX103 (1.5% Minocycline Topical Foam) in Subjects with Moderate-to-Severe Papulopustular Rosacea under Maximum-use Treatment Conditions

J Clin Aesthet Dermatol. 2021;14(3):E53–E57.  by Terry M. Jones, MD, and Iain Stuart, PhD Dr. Jones is with J&S Studies Inc., in College Station, Texas. Dr. Stuart is with VYNE Therapeutics Inc., in Bridgewater, New Jersey.  FUNDING: This study was sponsored by Foamix Pharmaceuticals Ltd., a wholly owned subsidiary of VYNE Therapeutics Inc. DISCLOSURES: Dr.

CONTINUE READING »